KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares Repurchased
Ratios

Royalty Pharma (RPRX) Receivables - Other (2019 - 2023)

Royalty Pharma's Receivables - Other history spans 5 years, with the latest figure at $14.2 million for Q4 2023.

  • For Q4 2023, Receivables - Other fell 15.38% year-over-year to $14.2 million; the TTM value through Dec 2023 reached $14.2 million, down 15.38%, while the annual FY2023 figure was $14.2 million, 15.38% down from the prior year.
  • Receivables - Other for Q4 2023 was $14.2 million at Royalty Pharma, down from $16.4 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $59.7 million in Q3 2021 and bottomed at $14.2 million in Q4 2023.
  • The 5-year median for Receivables - Other is $32.3 million (2020), against an average of $29.8 million.
  • The largest annual shift saw Receivables - Other soared 84.29% in 2021 before it plummeted 73.66% in 2022.
  • A 5-year view of Receivables - Other shows it stood at $33.5 million in 2019, then decreased by 1.1% to $33.2 million in 2020, then skyrocketed by 60.72% to $53.3 million in 2021, then crashed by 68.42% to $16.8 million in 2022, then fell by 15.38% to $14.2 million in 2023.
  • Per Business Quant, the three most recent readings for RPRX's Receivables - Other are $14.2 million (Q4 2023), $16.4 million (Q3 2023), and $16.4 million (Q2 2023).